MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
EPO treatment-related expenditures in MDS-RA patients were lowest with oral sucrosomial iron supplementation (Sideral®), with a longer interval between EPO administration in maintenance treatment, quicker hemoglobin recovery, lower ferritin increase and fewer blood transfusions.
|
31533096 |
2020 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
|
31650290 |
2020 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Correction to: The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
|
31788722 |
2020 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Effect of iron chelation therapy on EPO-STAT5 signalling pathway and EPO resistance in iron-overloaded low-risk myelodysplastic syndrome patients.
|
31838956 |
2020 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
In vivo studies demonstrate that pharmacological increase of serotonin levels using fluoxetine, a common antidepressant, has the potential to become an important therapeutic strategy in low-risk MDS anemia refractory to erythropoietin.
|
30893598 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This was a retrospective cohort study of 36 patients diagnosed with MDS and treated with EPO alfa at 30,000 to 60,000 IU per week.
|
31508719 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.
|
30549002 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The recent approval of epoetin alfa by the EMA in this setting will provide clinicians with a welcome, approved treatment option for lower-risk MDS.
|
31005849 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
|
31657156 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
|
30287621 |
2019 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
The decreased differentiation capacity of erythropoietin-pretreated mesenchymal stromal cells from patients with myelodysplasia could be restored by activating the Wnt pathway using lithium chloride or parathyroid hormone.
|
29079596 |
2018 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients).
|
29614393 |
2018 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
GeneticVariation
|
group |
BEFREE |
This double-blind, placebo-controlled study assessed the efficacy and safety of epoetin-α in IPSS low- or intermediate-1 risk (i.e., low-risk) MDS patients with Hb ≤ 10.0 g/dL, with no or moderate RBC transfusion dependence (≤4 RBC units/8 weeks).
|
29895954 |
2018 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Lower-risk MDS patients received deferasirox at 10 mg/kg/d (dispersible tablets) or 7 mg/kg/d (film-coated tablets) plus erythropoietin (n = 11), or erythropoietin alone (n = 12) for 24 weeks.
|
29777631 |
2018 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
The use of EPO in combination with G-CSF has been reported to synergistically improve erythroid responses in a group of patients with myelodysplastic syndromes who did not respond to EPO treatment alone; however, the mechanism remains unclear.
|
29720275 |
2018 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
However, the activation of these cells in the RA/RARS subgroup was impaired in EPO-untreated and enhanced in EPO-treated MDS patients.
|
27870945 |
2017 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.
|
28975386 |
2017 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
The role of myelodysplastic syndrome-related inflammatory proteins in endogenous erythropoietin regulation and response to erythroid-stimulating agents or lenalidomide has not been investigated.
|
28983059 |
2017 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To promote proliferation and differentiation of erythropoiesis, erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a large fraction of lower-risk MDS patients.
|
28958287 |
2017 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
|
26500139 |
2016 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Cytogenetic abnormalities and genomic copy number variations in EPO (7q22) and SEC-61(7p11) genes in primary myelodysplastic syndromes.
|
27282568 |
2016 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
|
27229713 |
2016 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
|
23596104 |
2013 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In two cases, thrombocytosis was under 1000×10(3)/μL and clinical evolution was similar to the myelodysplastic syndrome (transfusion dependent anemia with response to administration of erythropoietin).
|
24399021 |
2013 |
MYELODYSPLASTIC SYNDROME
|
0.400 |
Biomarker
|
group |
BEFREE |
Insulin receptor substrate 2 (IRS2) is an adaptor protein that associates with the receptor of erythropoietin, insulin-like growth factor 1 and thrombopoietin; however, its role is not known in myelodysplasia.
|
22465474 |
2012 |